openPR Logo
Press release

One "Target" for a Month: Creative Biolabs Features TNFRSF9

07-10-2024 08:20 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Getnews

/ PR Agency: PRChoices
One "Target" for a Month: Creative Biolabs Features TNFRSF9

Creative Biolabs introduces its range of TNFRSF9-related antibody reagents.
New York, USA - July 10, 2024 - The growing interest in TNFRSF9 (also known as CD137, 4-1BB) stems from its role as a co-stimulatory receptor on T cells, which can enhance immune responses against tumors. Research has shown that activating TNFRSF9 can significantly boost the efficacy of cancer immunotherapies. To synchronize with recent industry news highlighting the potential of TNFRSF9-targeted therapies to overcome the limitations of existing treatments and deliver durable anti-tumor responses, Creative Biolabs specifies their anti-TNFRSF9 engineered antibodies [https://www.creativebiolabs.net/symbolsearch_TNFRSF9_2.htm] in the monthly briefing.

Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg

I: Leading in with the Omnipresent Hi-Affi Trademark

"First of all, a short overview of our Hi-Affi Trademark platform to get you a clearer picture of our antibody performance," according to the scientist delivering the presentation, "which is a concert of advanced DNA technologies and powerful cell-free expression systems."

Almost all production work of recombinant antibodies [https://www.creativebiolabs.net/hi-affi-tm-recombinant-antibodies.htm] is run by the Hi-Affi Trademark platform, covering antibodies of different working modalities (blocking, neutralizing, etc.), antibodies against divergent targets (epitope-specific, mRNA encoded, etc.), and antibodies originated from different species (chicken, rabbit, etc.), with which the yielding reagents will be validated to have over 98% purity, high affinity, and reproducibility.

II: Catalog presentation

The scientist revealed a list of their research-use-only antibodies that are readily available for global delivery, and announced that the list is growing to cover more isotypes and more validated applications.

* Rat Anti-TNFRSF9 Recombinant Antibody

* Recombinant Mouse Anti-Human TNFRSF9 Antibody

* Hamster Anti-TNFRSF9 Recombinant Antibody

* Rat Anti-TNFRSF9 Recombinant Antibody

* Rat Anti-TNFRSF9 Recombinant Antibody

* Human Anti-TNFRSF9 Recombinant Antibody

* Human Anti-TNFRSF9 Recombinant Antibody

III: Case study: urelumab-a therapeutic breakthrough

Furthermore, a candidate that had received its final clinical results not a while ago was discussed-urelumab, an agonistic antibody targeting 4-1BB, making it a valuable tool in the fight against cancer. Two studies that evaluated urelumab in combination with cetuximab or nivolumab in patients with select, advanced solid tumors were reported in the paper.

"For relevant studies, we have anti-human 4-1BB recombinant antibodies [https://www.creativebiolabs.net/Anti-Human-4-1BB-Therapeutic-Antibody-Urelumab-13548.htm]," the scientist added, "which have been validated to be positive against native human antigen. Tested data are provided on the product page to help researchers know more about how they work in specific assays, like WB and ELISA."

IV: Outlook

Creative Biolabs prides itself on its commitment to innovation and collaboration and is poised to play a pivotal role in advancing TNFRSF9-targeted therapies.

"As the research community continues to explore the full potential of such critical factors in immunotherapy, we remain dedicated to driving scientific progress." The scientist summarized.

For more information about Creative Biolabs' TNFRSF9 antibodies and to explore their comprehensive product offerings, visit https://www.creativebiolabs.net or contact their expert team.

Company Overview

Creative Biolabs is a biotechnology company specializing in antibody development, engineering, and production. With a strong focus on innovation and customer service, Creative Biolabs provides a wide range of high-quality antibody products to support biomedical research and drug development worldwide.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email [http://www.universalpressrelease.com/?pr=one-target-for-a-month-creative-biolabs-features-tnfrsf9]
Phone: 1-631-830-6441
Country: United States
Website: https://www.creativebiolabs.net



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release One "Target" for a Month: Creative Biolabs Features TNFRSF9 here

News-ID: 3575212 • Views:

More Releases from Getnews

Overloop Launches AI-Powered Update to Simplify and Personalize Outbound Workflows
Overloop Launches AI-Powered Update to Simplify and Personalize Outbound Workflo …
Overloop, the AI-powered outbound platform built on more than 100,000 real campaigns, has released a major product update aimed at making outbound smarter, more strategic, and fully controlled by the teams who run it. The platform combines multichannel automation with a proprietary personalization engine that enables organizations to scale cold email and LinkedIn outreach while strengthening brand authority and reputation. Image: https://www.globalnewslines.com/uploads/2025/10/90dc47d69b6eb5627394a36e458e277d.jpg The release simplifies how organizations organize, personalize, and scale outbound
3E Accounting Group Achieves Breakthrough in Client Service with AI + Human Hybrid Model
3E Accounting Group Achieves Breakthrough in Client Service with AI + Human Hybr …
Novena, SG - October 7, 2025 - 3E Accounting, Asia-Pacific's first robotics-driven accounting firm, today announced breakthrough results in client service delivery through its innovative blend of artificial intelligence and human expertise. The company embeds AI into the very fabric of its operations, creating a hybrid service framework where consultants respond faster and smarter, while maintaining personal touch. This offers a sharp contrast to traditional models that rely solely on
Seissense Reprograms Performance Athleisure With PFAS-Free Designs and Sustainable Impact
Seissense Reprograms Performance Athleisure With PFAS-Free Designs and Sustainab …
Seissense [https://seissense.com], the UK-based premium athleisure brand, has launched a renewed vision: one that redefines the performance wear category through timeless design, technical clarity, and conscious materials. At its core lies a simple but powerful belief: Every Move Matters. Crafted to meet the needs of real people and real routines, Seissense blends elevated silhouettes with forward-thinking textile technologies, championing both wellness and innovation without compromise. All their pieces are PFAS-free by
J&G Fence Company Inc., Radio Personalities Joe Mayes and Jesse Caldwell III Gift Students with School Supplies
10-07-2025 | Arts & Culture
Getnews
J&G Fence Company Inc., Radio Personalities Joe Mayes and Jesse Caldwell III Gif …
Image: https://www.globalnewslines.com/uploads/2025/10/88201590ce9a9df0878484db522b32e9.jpg Gastonia, North Carolina - J&G Fence Company Incorporated, along with local WSGE 91.7FM (Gaston College) radio personalities Joe Mayes (far left of photo) and Jesse Caldwell III (far right of photo) recently donated a variety of school supplies to support local students. The generous gifts included Bluetooth computer keyboards, headsets, book bags, and Certificates of Excellence, all aimed at helping students feel prepared, motivated, and confident for the academic year. J&G

All 5 Releases


More Releases for TNFRSF9

Tumor Necrosis Factor Receptor Superfamily Member 9: North America to Retain its …
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) pipeline Target constitutes close to 35 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes. To evaluate factors influencing Tumor Necrosis Factor Receptor Superfamily Member 9, Market Research Hub (MRH) has included a report titled “Tumor Necrosis Factor Receptor